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A
 
BSTRACT
Background:
 
Atopic dermatitis (AD) is characterized
by repetitious eczematous skin and is Th2 dominant in
nature. Atopic dermatitis lesions have been observed
to improve in patients during viral or bacterial infec-
tion, such as herpes simplex virus (HSV). A Th1
pathway established to counter viral infection may
possibly be the mechanism for the relief of skin lesions
in AD.
 
Methods:
 
In animal AD models using NC/Nga mice,
the effects of local intra- and/or subcutaneous injec-
tion of ultraviolet inactivated-HSV were examined for
Th1/Th2 regulation through a negative regulation
pathway with suppressor of cytokine signaling
(SOCS)-3 and 5 using immunohistochemistry, 
 
in situ
 
hybridization and reverse transcription–polymerase
chain reaction.
 
Results:
 
Lesional skin of HSV-treated mice displayed
extensive interleukin (IL)-12p40-positive cellular infiltra-
tion compared with non-treated mice and IL-12p40/
signal transducers and activators of transcription (STAT)
4/SOCS5 mRNA expression was noted basically the
same in the three groups. Interleukin-4 receptor-posi-
tive cellular infiltrates in HSV-treated mice decreased
significantly more than in non-treated mice and IL-4
mRNA expression in the three groups was essentially
the same, but the expression of STAT6 and SOCS3
mRNA specific for the Th2 regulation pathway was
reduced more in HSV-treated compared with non-
treated mice. Expression of SOCS3 mRNA 
 
in situ
 
 in
HSV-treated epidermis underwent a far greater reduc-
tion compared with expression in non-treated mice.
 
Conclusions:
 
Ultraviolet-inactivated HSV treatment
would appear to induce a Th1 cellular response and
downregulate that of the Th2 pathway in AD-like
lesions of NC/Nga mice by bringing about a reduction
of SOCS3 expression in the skin. From the present
results, certain HSV DNA components may be effective
candidates for a new therapeutic approach in refrac-
tory AD.
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I
 
NTRODUCTION
 
Atopic dermatitis (AD) is an allergic disorder in which
Th2-mediated conditions are responsible, in part, for
the high IgE levels, with a past history of hereditary
atopic diathesis also being a factor for this immunolog-
ical deviation. Lymphocytes that infiltrate to AD lesional
skin in the initial phase of the disease are Th2-type cells
that produce Th2 cytokines,
 
1
 
 such as interleukin (IL)-4
and IL-5. Even in chronic stages of the disease, under
Th1-type conditions, interferon (IFN)-
 
γ
 
 production
 
2
 
 may
occur with or without IL-4. The pathomechanisms for
these processes are not completely understood. A safe
and effective therapy for this disease has yet to be
established, although steroid ointments and immuno-
suppressive agents, such as tacrorimus,
 
3
 
 have been
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found to be quite useful. Serious side-effects following
the application of these therapies may sometimes
occur.
There are some reports in the literature of improve-
ment of AD lesions during microbial infection.
 
4,5
 
 A
remarkable improvement has been noted during viral
infections, such as herpes simplex virus infection (HSV) or,
in particular, Kaposi’s varicelliform eruptions (VE).
 
6
 
 Either
human type I or type II HSV are responsible for gingivos-
tomatitis, herpes labialis, genital herpes and Kaposi’s VE.
Kaposi’s VE
 
6
 
 generally occur on the face and neck of AD
patients due to HSV infection, suggesting that impaired
cutaneous immunity may sometimes result from pro-
longed periods of steroid ointment application. A Th1
pathway established to counter viral infection may be the
mechanism for this improvement.
In some cases of microbial infection in humans and
animals involving innate and/or acquired immune sys-
tems,
 
7
 
 immunoregulatory neutrophils and macrophages
function to expell and/or kill the microbes. The pro-
inflammatory cytokine IL-12
 
7
 
 has been shown to be
involved in the susceptibility to microbial and viral infec-
tion caused by agents such as 
 
Listeria
 
8
 
 and HSV.
 
9
 
Induced Th1 cytokine IL-12 production to counter HSV
infection may be a factor essential for the improvement of
AD. The regulatory pathway for AD improvement sub-
sequent to HSV infection has been clarified.
In the present study, we were particularly interested in
the possibility of some negative regulatory control crucial
for the improvement of AD. Following the identification of
suppressor of cytokine signaling (SOCS),
 
10
 
 SOCS3
 
11
 
 and
SOCS5
 
12
 
 have recently been shown to bring about nega-
tive regulation of Th1 and/or Th2 conditions
 
13
 
 through
cytokine signaling control via the Janus tyrosine kinases
(JAK)–signal transducers and activators of transcription
(STAT) pathway
 
14
 
 in inflammatory diseases. It was demon-
strated that SOCS3
 
11
 
 is required for the negative regula-
tion of the Th1 pathway via IL-12 and STAT4, whereas
SOCS5
 
12
 
 negatively regulates the Th2 pathway via IL-4
and STAT6. The expression of SOCS3 may possibly
vary in proportion to the severity of allergic disorders,
although this would not necessarily be so in the case of
SOCS5 in allergic patients.
 
15
 
NC/Nga mice
 
16
 
 may be used as an animal model of
AD, because these animals develop dermatitis similar
to human AD. The disease is nearly always accompanied
by elevated serum IgE
 
17
 
 under ordinary conditions. The
clinical manifestation of dermatitis in the mice is severe
scratching behavior with consequent hair loss from the
head and back, deep excoriation and growth retardation.
Mites (
 
Myobia musculi
 
) inhabit mice as prasites (SLC Inc.
(Hamamatsu, Japan), pers. comm.) to possibly lead to
AD-like lesions. To date, in most human AD patients,
 
Dermatophagoides
 
 mites have been shown to cause AD.
 
18
 
The NC/Nga mice inherently manifest a Th2-dominant
immune response
 
16
 
 to allergens such as ovalbumin, as
also noted in human AD patients.
To determine the possibility and extent of Kaposi’s VE,
local intra- and/or subcutaneous injections of ultraviolet
(UV)-inactivated HSV were performed in order to examine
the effects of this agent on AD-like lesions mediated via a
negative regulation pathway with SOCS. Studies were
undertaken to determine whether HSV may produce
downregulation of the Th2 pathway by reducing SOCS3
expression, which may then improve AD lesions under the
dominant Th2 condition.
 
M
 
ETHODS
 
Mice
 
Male NC/Nga and BALB/c mice, 5 weeks of age, were
purchased from SLC Japan and housed under clean
conditions. The animals, kept in individual quarters,
were provided with standard chow and mineral water in
a conventional room without air conditioning.
 
Reagents
 
Reagents used were as follows: antimouse IL-4 receptor
(IL-4R; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), antimouse IL-12p40 (R&D Systems, Minneapolis,
MN, USA), antiphosphorylated STAT4 (Zymed Labora-
tories, San Francisco, CA, USA) and antiphosphorylated
STAT6 (Cell Signaling Technology, Beverly, MA, USA)
antibodies. The mouse IL-4 primer kit was obtained from
Maxim Biotechnology (San Francisco, CA, USA), the
catalyzed signal amplification (CSA) kit was from DAKO
(Glostrup, Denmark) the Takara Ex Taq kit was from
Takara Bio (Shiga, Japan), deionized formamide was
obtained from Ambion (Austin, TX, USA), protein K
(PCR grade) was from Roche (Mannheim, Germany),
triethanolamine (TEA) was from Wako Pure Chemical
(Osaka, Japan), RNase was from Roche and the 
 
in situ
 
hybridization solution and rabbit digoxigenin (DIG)/
horseradish peroxidase (HRP) antibodies were from
DAKO.
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Assessment of the severity of dermatitis in 
NC/Nga mice
 
The assessment of the severity of the dermatitis in the
mice was made essentially according to the scoring
method modified by Hiroi 
 
et al.
 
3
 
 as follows: 0, no
symptoms; 1, mild scratching; 2, moderate scratching
and/or mild hair loss; 3, severe scratching and/or severe
hair loss. Only mice with scores of more than 2 were
used in the present study.
 
Virus
 
Wild-type HSV type I was cultured in Vero cells with 10%
fetal calf serum (FCS; Gibco. Gaithersburg, MD, USA)
with Dulbecco’s modified Eagle’s medium (DMEM;
Nissui Pharmaceutical, Tokyo, Japan) supplemented
with 1% (v/v) streptomycin/penicillin and amphotericin-B
solution (Wako Pure Chemical) and 2 mmol/L 
 
L
 
-glutamine.
Cells were harvested in the medium at 1 
 
×
 
 10
 
7
 
 plaque
formation units (PFU). The HSV was inactivated with
200 mJ/cm
 
2
 
 UVB irradiation.
 
Examination procedure
 
Animal examination began at 10 weeks of age for all
mice, at which time hair loss corresponding to a score
of more than 2 was noted. Mice were grouped as
follows: six BALB/c mice (Bc) at 8–10 weeks of age and
four NC/Nga mice without skin lesions (Nn), even under
ordinary conditions, at 10 weeks of age were used as
negative controls; six NC mice at 10 weeks of age and
six NC mice at 15 weeks of age as non-treated mice;
and eight NC mice underwent 5 weeks treatment with
HSV. In HSV-treated mice, 2 
 
×
 
 10
 
5
 
 PFU UV-inactivated
HSV diluted with basic DMEM was injected intra-
cutaneously and/or subcutaneously under diethyl ether
anesthesia at six sites extending from the head to back
(Fig. 1) on every other day for 5 weeks. At 10 and
15 weeks, the animals were killed. As negative controls
for the FCS supplemented DMEM, three NC/Nga and
three BALB/c mice were treated with 0.2 mL medium
only per injection for 5 weeks. Skin specimens were
obtained from the heads and backs of animals and, in
the case of mice treated with HSV, obtained at 48 h
following the final injections, frozen immediately at
–20
 
°
 
C in tissue compound Tissue-Tek (Miles, Austin,
TX, USA) and stored at –80
 
°
 
C until use.
 
Immunohistochemistry
 
Immunohistochemistry was performed according to the
polymer-complex method (peroxidase-labeled polymer
conjugated to antirabbit and antimouse immuno-
globulins) of the EnVision system (DAKO) with diamino-
benzidine (DAB) for IL-4R/IL-12p40 and phosphorylated
(p) STAT4/6 as chromogenic substances. As a nega-
tive control, no polymer secondary antibodies were
used.
Cryostat sections (7 
 
µ
 
m) from skin specimens were
placed separately on resin-coated glass slides and fixed
in cold acetone for 5 min.
The primary antibodies (IL-4R, IL-12p40, p-STAT4
and p-STAT6), diluted with Tris-buffered saline (TBS;
pH 7.6) to a final concentration of 
 
×
 
40, were incubated
with EnVision polymer secondary antibody reagent for
1 h at room temperature. Residual antibodies were sub-
sequently absorbed with normal mouse serum mixed
with the antibody complex for 30 min at room tempera-
ture. Sections were washed with TBS and preblocked
with intracellular peroxidase containing blocking agent
(0.3% H
 
2
 
O
 
2
 
) for 5 min. Protein blocking (DAKO) was
conducted for 10 min and sections were incubated with
the primary and secondary antibody complexes for 1 h
at room temperature. After being washed with TBS,
all tissue samples were incubated with a chromogenic
substance. The chromogenic reaction was terminated
with water and counter-staining was performed with
hematoxylin.
 
Fig. 1
 
Time-course and sites of injection of ultraviolet-
inactivated herpes simplex virus indicated as filled circles on the
mouse’s back.
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Total RNA extraction
 
Total RNA from 50–100 mg (weight of whole skin)
samples from the heads and backs of the animals was
extracted in accordance with the manufacturer’s instruc-
tions using the Fast RNA kit Green (BIO 101, Irvine, CA,
USA). The RNA concentration was measured and
expressed as 
 
µ
 
g/mL using a Spectrometer ND-1000
(NanoDrop Technologies, Wilmington, DE, USA).
 
Reverse transcription–polymerase chain 
reaction
 
Reverse transcription (RT) was performed with 2 
 
µ
 
g total
RNA using an oligo primer and a Ready TO GO RT-PCR
Beads kit (Amersham Biosciences, Buckinghamshire, UK).
To amplify specific cDNA, the following primers were
used for polymerase chain reactions (PCR): mouse IL-4
(371 bp, ref. NM021283, Maxim Biotechnology), 5
 
′
 
-CACT
GACGGCACAGAGCTATTGATG, 3
 
′
 
-TCATGGTGCAGC
TTTCGATGAATC; mouse IL-12p40 (412 bp, ref.
NM008352), 5
 
′
 
-TTCAATCAGGGCTTCGTAGG, 3
 
′
 
-
TAGACAAGCACACTGCCGTC; mouse STAT4 (354 bp,
ref. AY400721), 5
 
′
 
-CCTGGGTGGACCAATCTGAA,
3
 
′
 
-CTCGCAGGATCGTCAGCGAA; mouse STAT6
(1300 bp, ref. NM009284), 5
 
′
 
-TCACTGGGGGAC
CGGATCCGGGATCTT, 3
 
′
 
-GCGCTCAGCTCGGGC
CTACACGCATTA; mouse SOCS3 (314 bp, ref.
NM007707), 5
 
′
 
-CTTCAGCTCCAAGACTCGAGT, 3
 
′
 
-
AACACCAGGGATCTTCCT; mouse SOCS5 (413 bp,
ref. BC053015), 5
 
′
 
-GCCTTACAGCTGGGACTGAG,
3
 
′
 
-AGTGGCTTTGACTGCTTGCT; mouse thymus and
activation-regulated chemokine (TARC; 600 bp, ref.
19), 5
 
′
 
-AACTTCACCAGTACTAGGACA, 3
 
′
 
-GGTTCGC
CTGTAGTGCATAA; and mouse GAPDH (320 bp, ref.
XM284785), 5
 
′
 
-GCCAAGGTCATCCATGACAACTTTGG,
3
 
′
 
-GCCTGCTTCACCACCTTGATGTC. Amplification was
conducted for 35 cycles at 94
 
°
 
C for 1 min (for STAT6,
pre-85
 
°
 
C denaturation), at 55
 
°
 
C for 1 min and 72
 
°
 
C
for 1 min in all PCR reactions, except for the 40 cycle
PCR reaction for TARC and IL-4. Polymerase chain
reaction-amplified fragments were fractionated on a
1.5% agarose gel.
 
In situ
 
 hybridization
 
This process was performed using DIG-labeled oligo-
probes for mouse SOCS3 (ref. NM007707), antisense
GGCATGTAGTGGTGCACCAGCTTGATACACAGT
CGAAGC and sense GCTTCGACTGTGTACTCAA
GCTGGTGCACCACTACATGCC. (Kurabo Industries,
Osaka, Japan). Briefly, paraffin-embedded skin samples,
subsequent to 4% paraformaldehyde fixation, were
deparaffinized and treated with 20 
 
µ
 
g/mL protein K
for 30 min at 37
 
°
 
C. After phosphate buffer washing,
samples were treated with 0.25% acetic anhydride in
0.1 mol/L TEA and then 3% H
 
2
 
O
 
2
 
 for 60 min. Sections
were incubated with DIG-labeled SOCS3 antisense or
sense oligo-probes dissolved in 
 
in situ
 
 hybridization solu-
tion (DAKO) preheated at 85
 
°
 
C for 1 min and then
overnight at 50
 
°
 
C. After hybridization, slides were
washed in 2
 
×
 
 standard saline citrate (SSC)/50% forma-
mide for 30 min at 55
 
°
 
C and TNE buffer (10 mmol/L
Tris-HCl, 0.5 mol/L NaCl, 1 mmol/L EDTA) at 37
 
°
 
C for
10 min and then digested with 10 
 
µ
 
g/mL RNase at
37
 
°
 
C for 30 min. Sections were washed with 2
 
×
 
 SSC,
0.2
 
×
 
 SSC and 0.1
 
×
 
 SSC and TBS with Tween wash.
Following protein blocking, sections were incubated with
rabbit DIG/HRP antibodies diluted in 1
 
/
 
400 for 15 min.
Further steps were performed using the DAKO CSA
system and finally SOCS3 mRNA expression was deter-
mined with diaminobenzidine (DAB) solution. Counter-
staining was performed with heamatoxylin.
 
R
 
ESULTS
 
Clinical evaluation
Seven of eight HSV-treated mice showed a remarkable
reduction in hair loss and scratch dermatitis (Fig. 2). In
the groups of non-treated NC/Nga mice, severe hair
loss on the head and back and remarkable growth
retardation (Fig. 2) were evident in all cases (n = 12).
In the control group (injections of 10% FCS supple-
mented DMEM; n = 3), no clinical improvement was
observed after 5 weeks DMEM treatment. The DMEM-
treated BALB/c mice displayed no change in clinical
appearance.
Light microscopic evaluation
The epidermis of BALB/c mice was thin, with only one to
a few epidermal cell layers present (Fig. 3a), and did not
contain cellular infiltrates. Non-affected NC/Nga mice
(negative controls) showed mild acanthosis (Fig. 3b),
even though, clinically, there was no hair loss. Histolog-
ical examination of non-treated NC/Nga mice displayed
extensive acanthosis and dermal cellular infiltration
(Fig. 3c); however, in HSV-treated animals, reduced
acanthosis (Fig. 3d) with dermal infiltrates was evident.
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TARC mRNA expression as an indicator of an 
improvement in skin lesions
In all non-treated NC/Nga mice, TARC mRNA could be
detected in the whole skin. In all seven HSV-treated mice
whose condition improved with treatment (data for five
mice including one mouse without improvement) and
control mice, TARC mRNA was absent in skin samples
(Fig. 4).
Immunohistochemical staining
Interleukin-12p40/p-STAT4
In non-treated NC/Nga mice, only a few IL-12p40-
(Fig. 5a) and p-STAT4-positive (Fig. 5c) cells had infil-
trated the lesional skin, whereas in mice treated for
5 weeks with HSV many IL-12p40- (Fig. 5b) and p-STAT4-
positive (Fig. 5d) cells could be seen. In contrast, in
BALB/c and non-affected NC/Nga mice (negative con-
trols) only a few or no positive cells were present.
Interleukin-4R/p-STAT6
Extensive IL-4R- (Fig. 6a) and p-STAT6-positive (Fig. 6c)
cellular infiltrates were particularly abundant in non-
treated mice at 15 weeks. In HSV-treated NC/Nga mice,
IL-4R- (Fig. 6b) and p-STAT6-positive (Fig. 6d) cellular
infiltrates had decreased to a far greater extent than in
the non-treated mice. In BALB/c and non-affected mice
(negative controls), only a few or no positive cells could
be detected.
Fig. 2 Clinical evaluation. A remarkable improvement, result-
ing in nearly intact head and back hair, following treatment with
ultraviolet-inactivated herpes simplex virus at 5 weeks (mouse
aged 15 weeks) was seen compared with non-treated NC/Nga
mice, which showed severe hair loss and impaired body growth.
Fig. 3 Histology of the skin. (a)
Results for BALB/c mice showing
a thin epidermis and no cellular
infiltration. (b) Results for non-
affected NC/Nga mice showing
slight acanthosis with mild cellu-
lar infiltrates, even though the
mice were clinically without hair
loss. (c) Results for skin from a
non-treated NC/Nga mouse
showing extensive acanthosis
with cellular infiltrates, com-
pared with (d) skin from a herpes
simplex virus-treated mouse
showing reduced acanthosis
even with the presence of der-
mal infiltrates. (Original magni-
fication ×100.)
Fig. 4 Evaluation of the Th2 chemokine thymus and activa-
tion-regulated chemokine (TARC). All non-treated NC/Nga
mice (data for six mice) were positive for TARC mRNA expres-
sion in whole skin. However, in the case of all herpes simplex
virus-treated mice who showed improvement, except for one
mouse without improvement, no TARC mRNA expression was
present in the skin.
336 Y HORIUCHI ET AL.
Reverse transcription–polymerase chain 
reaction analysis
The Th1 pathway (Fig. 7)
The mRNA expression of IL-12p40, STAT4 and SOCS5
was essentially the same in the control, non-treated and
HSV-treated groups (Fig. 7). The mRNA expression of
STAT4 in HSV-treated mice was somewhat greater com-
pared with non-treated mice.
The Th2 pathway (Fig. 8)
Interleukin-4 mRNA expression in the whole skin may
be very slight and, thus, would not differ significantly in
any of the three groups. In all HSV-treated mice, IL-4
mRNA expression was virtually absent. However, STAT6
and SOCS3 mRNA expression was considerably
reduced in HSV-treated mice compared with non-
treated animals.
Fig. 5 Immunohistochemical
staining for interleukin (IL)-
12p40/phosphorylated signal
transducers and activators of
transcription (p-STAT) 4 as Th1
factors. In non-treated NC/Nga
mice, only a few (a) IL-12p40-
and (c) p-STAT4-positive cells
have infiltrated the lesional der-
mis. In mice treated for 5 weeks
with herpes simplex virus, many
(b) IL-12p40- and (d) p-STAT4-
positive cells are present. (Orig-
inal magnification ×200.)
Fig. 6 Immunohistochemical
staining for interleukin-4 recep-
tor (IL-4R)/phosphorylated sig-
nal transducers and activators of
transcription (p-STAT) 6 as Th2
factors. Extensive (a) IL-4R- and
(c) p-STAT6-positive cellular
infiltrates were particularly evi-
dent in non-treated mice at
15 weeks. In herpes simplex
virus-treated NC/Nga mice, (b)
IL-4R- and (d) p-STAT6-positive
cellular infiltrates had decreased
significantly compared with
those in non-treated mice.
(Original magnification ×200.)
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In situ hybridization of SOCS3
The expression of SOCS3 was quite pronounced in the
epidermis and dermal cellular infiltrates of non-treated
mice (Fig. 9a), whereas SOCS3 expression was weak in
HSV-treated mice (Fig. 9b) compared with the sense
negative control (Fig. 9c).
Results for negative control animals treated 
with only basic FCS-supplemented DMEM
The mRNA expression of TARC/STAT6 (as a Th2 factor)
and STAT4/IL-12p40 (as a Th1 factor) in whole skin
from DMEM-treated NC mice was the same. Results for
DMEM-treated BALB/c mice were the same as results
for  non-treated BALB/c and DMEM-treated NC/Nga
mice and as DMEM-treated NC/Nga and non-treated
positive control NC/Nga mice. A few cellular infiltrates
could be seen in DMEM-treated mice (data not shown).
DISCUSSION
Clinical features of hair loss and scratch dermatitis,
extensively evident in non-treated NC/Nga mice, were
improved quite remarkably in seven of eight UV-
inactivated HSV-treated NC/Nga mice. The serum Th2
chemokine TARC has been taken as indicator of the
clinical severity of AD patients20 and high expression of
TARC in the basal epithelium of NC/Nga mice21 with
skin lesions is consistent with the findings of the present
study in which TARC mRNA expression from whole skin
of the head and back decreased in UV-inactivated HSV-
treated mice who showed an improvement of AD-like
lesions. The infiltration of IL-12p40- and p-STAT4-positive
cells as Th1 phenotypic cells was quite extensive com-
pared with that in non-treated mice. The expression of
STAT6 and SOCS3 mRNA, both Th2-dominant factors,
was considerably more reduced in UV-inactivated HSV-
treated mice compared with non-treated mice. Thus,
HSV may possibly require biphagic effects, one for Th1
cellular induction and the other for inhibition of Th2
regulatory response.
Atopic dermatitis lesions are generally taken to indi-
cate Th2 dominance,22 particularly in the acute phase of
AD. Still, both Th2 and Th1 dominance may be possible
at the same time and be cross-regulated. A shift of
dominance from one to the other in skin lesions may be
essential for the ultimate control and reduction of AD.
Fig. 7 mRNA expression for the Th1-related pathway. The
expression of interleukin (IL)-12p40, signal transducers and
activators of transcription (STAT) 4 and suppressor of cytokine
signaling (SOCS) 5 mRNA was basically the same for control,
non-treated and herpes simplex virus (HSV)-treated groups. The
expression of STAT4 mRNA in HSV-treated mice was somewhat
greater (albeit not significantly) compared with non-treated mice.
Fig. 8 mRNA expression for the Th2-related pathway. (a) The
expression of interleukin (IL)-4 mRNA in whole skin is possibly
very slight, so that expression in the three groups was found to
be essentially the same, although expression was detected in
only one herpes simplex virus (HSV)-treated mouse. Strong
mRNA expression of signal transducers and activators of tran-
scription (STAT) 6 was found in all non-treated NC/Nga mice,
but reduced expression was observed in HSV-treated NC/Nga
mice. Note reduced suppressor of cytokine signaling (SOCS)
3 mRNA expression in HSV-treated NC/Nga mice. (b) The
intensity of the reverse transcription–polymerase chain reaction
band for SOCS3 is expressed destiometrically normalized to
that for GAPDH. Expression of SOCS3 mRNA in HSV-treated
NC/Nga mice, except for the one mouse that showed no
improvement in clinical features, was significantly reduced
(P < 0.05) compared with non-treated mice.
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Regulatory pathways involved in the improvement of
human AD subsequent to the onset of microbial infection,
such as Kaposi’s VE, and AD-like lesions in NC/Nga
mice with microbial components are areas of research
that have been given little attention to date. An investiga-
tive report to clarify the mechanism of improved skin
lesions in AD patients infected with varicella zoster virus
(VZV)23 appears to be the only report in the literature. The
Th1-dominance in T cells that infiltrate the skin may
essentially improve Th2-dominant AD lesions via the
local production of IL-12 brought about in response to
VZV antigens in the lesions.23
The Th1 response to microbe components is important
in the host defense against microbe infection, such HSV.9
In NC/Nga mice under ordinary conditions, a defective
Th1 immune response24 to bacterial stimulation has been
noted, with consequent Th2 induction and a favorable
effect on dermatitis. In cases of HSV infection, IL-12 has
been shown clearly to enhance susceptibility to viral
infection.9 Herpes simplex virus infection in mice stimu-
lates mainly the Th1-phenotype CD4+ T cell response25
to virus components. Interleukin-12 inhibits T cell differ-
entiation into IL-4-secreting Th2 phenotypic cells and
suppresses IgE production.26 Interleukin-12 production is
brought about by cell activation due to bacterial and viral
products that have been shown to enhance the innate
immune response7 by regulating IL-12. This regulation in
human allergic disease through the action of microbial
components has provided a basis for the establishment of
more highly effective therapeutic approaches. Extensive
IL-12p40-positive cell infiltration in the lesional skin of
HSV-treated mice was observed in the present study.
Interleukin-12p40 mRNA expression from whole skin was
essentially the same in all three groups. Interleukin-12
mRNA expression is considerable in keratinocytes,27
where IL-12 proteins may not be detectable in the epi-
dermis by immunohistochemistry, and this may be a
possible explanation for these observations.
Heat- or UV-inactivated HSV has been shown to
induce IL-12p40 production28 from T cells to a lesser
extent, even after costimulation with IFN-γ. Induction of
IL-12 by UV-inactivated HSV may be less than by living
viruses.9 The present study clearly demonstrates a clinical
improvement in AD-like lesions in NC/Nga mice, a
marked Th1 type cellular infiltration in the lesional dermis
and inhibition of Th2-related STAT6 and SOCS3 induc-
tion, which may be governed by injections of UV-
inactivated HSV. Even UV-inactivated HSV may serve
quite effectively to control AD lesions. Herpes simplex
virus was used in the present study at 2 × 105 PFU/mouse
per injection and injection of more than this may possibly
improve AD-like lesions to a greater extent. The design of
the present study was based on Kaposi’s VE model for a
very localized response in which there is no systemic
effect on viral infection. Thus, there is a need to develop
treatment with greater therapeutic potential. A separate
study on the dose of HSV should be undertaken.
The authors attach great importance to the possibility
of negative regulatory control as the factor most crucial
to the improvement of AD. It is of particular interest that
SOCS have recently been found to serve as a negative
regulatory system for the Th1/Th2 pathway, this being
especially so for SOCS3 and/or SOCS5 of the SOCS
family.10 The SOCS proteins10 are generally present in
small amounts in cells and their production comes about
transcriptionally in response to stimulation by various
cytokines. The mRNA expression of SOCS3 was found in
the present study to be less in UV-inactivated HSV-treated
mice than in non-treated mice and the results of
in situ hybridization of the skin lesions indicate that
Fig. 9 Suppressor of cytokine
signaling (SOCS) 3 mRNA
expression by in situ hybridization.
Intense expression of SOCS3 was
evident in the epidermis and
dermal cellular infiltrates of non-
treated mice (a), but was weak
in herpes simplex virus-treated
NC/Nga mice (b) compared
with the sense negative con-
trol (c). (Original magnification
×200.)
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UV-inactivated HSV apparently reduces SOCS3 expres-
sion in lesional skin, with a possibly consequent inhibition
of Th2 regulation. The STAT proteins apparently mediate
the inhibition of SOCS gene expression.10 It has been
shown that STAT429 is the most critical for the activation
of the transcription factor and leads to the expression of
IL-12 bioactivity and Th1 development; STAT629 regu-
lates the response to allergic stimuli for the development
of Th2 cells. Interleukin-4R- and STAT6-positive cells are
considerably fewer in non-atopic compared with atopic
subjects.30 The results of immunohistochemical staining
in the present study indicate cell infiltration with IL-4R and
p-STAT6 expression to be significantly less in HSV-treated
mice and IL-12p40- and p-STAT4-positive cellular infil-
trates in HSV-treated mice to be markedly greater than
in non-treated mice. Thus, the Th1 response may be
induced by UV-inactivated viral application with a con-
sequent reduction in SOCS3 expression in the skin. This
should serve as a basis for developing therapy for treating
AD lesions. Following a reduction in SOCS3 expression
as a Th1 negative regulator, Th2 conditions may be sup-
pressed. Reduction of SOCS3 expression may be essen-
tial to the reduction of atopic lesions and it then follows
that control of SOCS3 should serve as a new therapeutic
means for treating AD. The mRNA expression of SOCS5
was found to be essentially the same in normal, non-
treated and HSV-treated mice. The expression of SOCS3
may be in proportion to the severity of AD,15 but this
may not be the case for SOCS5. Suppressor of cytokine
signalling-131 is uniquely required for the negative regu-
lation of IFN-γ signaling and suppresses CD23 expres-
sion induced by IL-4.32 The Th1 type cytokine IFN-γ may
be necessary as an immune factor for the clearance of
HSV33 from cutaneous sites of infection. Accordingly, the
regulatory mechanism for HSV-mediated improvement of
AD and AD-like lesions may cross-regulate between
SOCS through the JAK-STAT pathway.
Antimicrobial peptides7 have been shown to have key
functions in the innate immune system, which is the first
line of defense against microbes that have invaded the
skin. Cytokines are produced early through the innate
immune response towards microbes such HSV.34 The
DNA from HSV may induce innate immunity and,
recently, DNA products of HSV have been shown to
possibly to give rise to a toll-like receptor (TLR) 9/MyD88
innate pathway34 that activates a Th1-type immuno-
regulatory response. The western blotting results shown in
Fig. 10 indicate enhanced expression of (TLR9) from skin
samples of HSV-treated mice exceeds that in control or
non-treated mice. Additional investigations may reveal
the reasons for this. Investigations of gene products of
HSV, which may lead to greater Th1 dominance and a
reduction in the Th2 response in AD lesions through
innate immunoregulatory pathways, should be under-
taken so as to arrive at safer and more effective treat-
ments for AD.
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